/People

Thierry Mauvernay

Investor

President, Delegate of the Board, Debiopharm International SA at Debiopharm Innovation Fund · Board director at Medable

Find your path to Thierry

31 people in our graph can introduce you to Thierry.

Each arrow is one introduction. Sign up to fill in the first one.

Ask Anarghya Vardhana to introduce you to Thierry

You →Anarghya · together at Medable →Thierry

Ask Jamie Chen to introduce you to Thierry

You →Jamie · 7 people · together at Medable →Thierry

Ask Sam Okafor to introduce you to Thierry

You →Sam · 4 people · together at Debiopharm Innovation Fund →Thierry

Sign up to find every way you can get introduced to Thierry

  • Your email: the people you already email who know Thierry
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with Thierry
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

About

President of Après-demain, the parent holding company of Debiopharm, and chairman of the investment committee of the Debiopharm Innovation Fund. He previously worked as an entrepreneur in the international cosmetics industry and holds a Master of Science in Economics and Marketing and an MBA.

Board director at Medable

Intro paths

→

In turn, Thierry can intro founders to Medable's investors below.

Co-founders at Medable

MLMichelle Longmire
Michelle LongmireFounder
TR
Timothy R. SmithExecutive Officer, Director
TS
Tim SmithFounder

Colleagues at Debiopharm Innovation Fund

Frequently asked questions

Who is Thierry Mauvernay?
President of Après-demain, the parent holding company of Debiopharm, and chairman of the investment committee of the Debiopharm Innovation Fund. He previously worked as an entrepreneur in the international cosmetics industry and holds a Master of Science in Economics and Marketing and an MBA.
Where does Thierry Mauvernay work?
Thierry Mauvernay is President, Delegate of the Board, Debiopharm International SA at Debiopharm Innovation Fund.